-

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acutus Medical, Inc. (AFIB) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) investors concerning the Company’s possible violations of federal securities laws.

On November 11, 2021, Acutus announced that it was slashing its 2021 revenue guidance from a range of $22 million to $33 million down to a range of $17 million to $17.5 million. The Company attributed the revision in substantial part to on the Company’s adoption of a new commercialization strategy focused on system relocations, sales training, and system utilization. During a conference call held the same day, the Company revealed that it had removed and repositioned approximately 20% of its AcQMap systems under evaluation arrangements during the prior quarter. The Company also admitted that these systems had been experiencing below-target utilization and that relocating such a large portion of the Company’s installations would negatively impact Acutus’ growth.

On this news, Acutus’s share price fell $3.02, or 45.3%, to close at $3.64 on November 12, 2021, thereby injuring investors.

If you purchased Acutus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NASDAQ:AFIB

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Law Offices of Howard G. Smith Encourages Lufax Holding Ltd. (LU) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Lufax Holding Ltd. (“Lufax” or the “Company”) (NYSE: LU) securities between April 7, 2023 and January 26, 2025, inclusive (the “Class Period”). Lufax investors have until May 20, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LUFAX HOLDING LTD. (LU), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE...

Law Offices of Howard G. Smith Encourages Gemini Space Station, Inc. (GEMI) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ: GEMI) investors who purchased Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about September 12, 2025 (the “IPO” or “Offering”) and/or securities between September 12, 2025 and February 17, 2026, inclu...

Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”). Atara investors have until May 22, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATARA BIOTHERAPEUTICS, INC. (ATRA), CONTACT THE LAW OFFICES OF HOWARD G. S...
Back to Newsroom